Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Short-Term Debt & Capital Lease Obligation : $6,359 Mil (As of Mar. 2024)

View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Bristol-Myers Squibb Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6,359 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Bristol-Myers Squibb Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $51,050 Mil.

Bristol-Myers Squibb Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Bristol-Myers Squibb Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Short-Term Debt & Capital Lease Obligation Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

3,479.00

2,504.00

5,117.00

4,400.00

3,281.00

Bristol-Myers Squibb Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															2,923.00	3,188.00	5,617.00	3,281.00	6,359.00

Bristol-Myers Squibb Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Bristol-Myers Squibb Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Executives

Christopher S. Boerner	officer: EVP, Chief Commercial Officer	21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii	director	1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman	officer: EVP, Corporate Affairs	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge	officer: SVP, Human Resources	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge	officer: EVP, Chief Research Officer	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey	officer: Pres., Research & Early Dev.	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky	officer: EVP, Chief Commercial Officer	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio	officer: EVP & Chief Commercial Officer	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins	officer: EVP, Chief Financial Officer	C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt	director	BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung	officer: Vice President and Secretary	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees	officer: SVP & Controller	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan	officer: EVP, Glob. Prod. Dev. & Supply	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers	officer: EVP, Chief Digital & Tech Off.	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von	officer: SVP, Enterp. Services & CIO	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543